Name of opportunity: 👀
Merck & Co. Inc.
$3 billion offer 💰
Pharmaceutical company Merck & Co has seen an increase in price over the past day, as shares have gone up by 1.46%. This might be because the company recently revealed that it put a $3 billion offer to buy Moon Lake Immunotherapeutics.
Merck & Co is an income stock, which means it pays out a portion of its profits to shareholders through dividends. Merck & Co’s dividend yield is 4.04%, which means if you invested $1000 you might be paid $40.40 a year in dividends (based on the last 12 months).
The average analyst recommendation for Merck & Co is ‘buy’.
How hot is this investment opportunity? 🔥🔥🔥
Analysts predict the price of Merck & Co. Inc. might increase from $78.27 to $130.75 in the next 12 months. If you invested $1000, you might profit $670.55.
Merck & Co recently offered to buy MoonLake Immunotherapeutics for $3 billion, which was rejected, but talks might be revived. MoonLake are set to reveal final phase test results for its drug sonelokimab (SLK) to help treat hidradenitis suppurativa, which is a painful, long-term skin condition.
If Merck successfully bought MoonLake, the company would acquire SLK, which might help to grow revenue.This might have attracted investors to Merck, boosting their confidence in the company which might be the reason behind the recent rise in share price. Growing company MoonLake also recently received $500 Million in funding from Hercules Capital.
Pharmaceutical company 💊
Merck & Co is an American pharmaceutical multinational company, and is one of the largest pharmaceutical companies in the world. The company is headquartered in Rahway, New Jersey, United States.
Which neme?: 🔍
‘Pharma’, ‘Low Volatility Stocks’
Download Nemo.Money to check out Merck & Co. New users can grab our registration bonus up to a maximum of $50 on first deposit. Terms and conditions apply.
